Sign inJoin waitlistJoin the waitlist

Mitesh Borad

Associate Professor of Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · · ·

History

Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Medical Oncology Tulane University School of Medicine
2003–2005
Internal Medicine
Cedars-Sinai Medical Center
2000–2003
University of Medicine and Dentistry of New Jersey
1996–2000

Research

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
The Lancet Oncology · 2020 · 1,293 citations
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Oncology · 2020 · 904 citations
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
Journal of Clinical Oncology · 2011 · 883 citations

Tanios Bekaii-Saab
63 papers
Daniel Ahn
43 papers · 2 as a fellow
Lewis Roberts
40 papers
Mohamad Sonbol
39 papers · 3 as a fellow
Hani Babiker
32 papers
Amit Mahipal
29 papers
Milind Javle
27 papers
DH
Daniel Von Hoff
25 papers
KM
Kabir Mody
23 papers
Robert McWilliams
23 papers
RR
Ramesh Ramanathan
22 papers
Gregory Gores
21 papers

Grants

New Therapuetics for Pancreatic Cancer
National Cancer Institute · R01
PI · $1.8M · Mayo Clinic Rochester
2022–2027
Mayo Clinic Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $303.3K · Mayo Clinic Rochester
1997–2025
HRD-IA Signatures in Pancreatic Ductal Adenocarcinoma
National Cancer Institute · UH3
Contact PI · $325.7K · Mayo Clinic Arizona
2022–2025
Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular Carcinoma
Food and Drug Administration · R01
Contact PI · $399.2K · Mayo Clinic Arizona
2014–2020

Clinical trials

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Principal investigator · Terminated · Phase 1
Mayo Clinic
2024–2025
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
Principal investigator · Completed · Phase 2
RedHill Biopharma Limited
2018–2022
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Principal investigator · Completed · Early phase 1
Mayo Clinic
2016–2018
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Principal investigator · Terminated · Phase 1
Vivolux AB
2015–2016